mavoglurant (STP7) / Novartis, STALICLA  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
mavoglurant (STP7) / STALICLA
Parkinson disease-1: AFQ056 in Phase III development for the treatment of Parkinson's disease levodopa-induced dyskinesia.

Ongoing
3
0
RestOfWorld
mavoglurant (AFQ056)
Novartis
Parkinson's Disease
 
 
NCT01433354 / 2011-002379-40: Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)

Terminated
2/3
119
US, Europe, RoW
AFQ056
Novartis Pharmaceuticals
Fragile X Syndrome
09/14
09/14

Download Options